Long-Term Stimulant Treatment Affects Brain Dopamine Transporter Level in Patients with Attention Deficit Hyperactive Disorder
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Brain dopamine dysfunction in attention deficit/hyperactivity disorder (ADHD) could explain why stimulant medications, which increase dopamine signaling, are therapeutically beneficial. However while the acute increases in dopamine induced by stimulant medications have been associated with symptom improvement in ADHD the chronic effects have not been investigated. METHOD: We used positron emission tomography and [(11)C]cocaine (dopamine transporter radioligand) to measure dopamine transporter availability in the brains of 18 never-medicated adult ADHD subjects prior to and after 12 months of treatment with methylphenidate and in 11 controls who were also scanned twice at 12 months interval but without stimulant medication. Dopamine transporter availability was quantified as non-displaceable binding potential using a kinetic model for reversible ligands. RESULTS: Twelve months of methylphenidate treatment increased striatal dopamine transporter availability in ADHD (caudate, putamen and ventral striatum: +24%, p<0.01); whereas there were no changes in control subjects retested at 12-month interval. Comparisons between controls and ADHD participants revealed no significant difference in dopamine transporter availability prior to treatment but showed higher dopamine transporter availability in ADHD participants than control after long-term treatment (caudate: p<0.007; putamen: p<0.005). CONCLUSION: Upregulation of dopamine transporter availability during long-term treatment with methylphenidate may decrease treatment efficacy and exacerbate symptoms while not under the effects of the medication. Our findings also suggest that the discrepancies in the literature regarding dopamine transporter availability in ADHD participants (some studies reporting increases, other no changes and other decreases) may reflect, in part, differences in treatment histories.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, almost all imaging studies on neurotransmitters have been performed in patients that received (chronic) pharmacotherapy, which may have influenced the scan directly, due to competition of the drug with a radioligand for a specific binding site, or indirectly because the brain adapts to the pharmacological effects (Wang et al., 2013).”
From Response Inhibition and Interference Control in Obsessive–Compulsive Spectrum Disorders (2014) · cites this paper as Wang et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, almost all imaging studies on neurotransmitters have been performed in patients that received (chronic) pharmacotherapy, which may have influenced the scan directly, due to competition of the drug with a radioligand for a specific binding site, or indirectly because the brain adapts to the pharmacological effects (Wang et al., 2013).”
From Response Inhibition and Interference Control in Obsessive–Compulsive Spectrum Disorders (2014) · cites this paper as Wang et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“research has shown that chronic MPH application is able to upregulate striatal dopamine turnover (Wang et al., 2013).”
From Differentiating neural reward responsiveness in autism versus ADHD (2014) · cites this paper as Wang et al., 2013
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In another study, in adults with ADHD, long-term MPH treatment increased striatal DAT availability (216).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Logan, J., Fowler, J. S., Volkow, N. D., Wolf, A. P., Dewey, S. L., Schlyer, D. J., MacGregor, R. R., Hitzemann, R., Bendriem, B., Gatley, S. J., et al. (1990) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1990.127 · Cited by 1,479
Self-citationVolkow, N. D., Wang, G.-J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y.-S., Hitzemann, R., & Pappas, N. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1325 · Cited by 885
Self-citationEvaluating Dopamine Reward Pathway in ADHD: Clinical Implications
Volkow, N. D., Wang, G.-J., Kollins, S. H., Wigal, T. L., Newcorn, J. H., Telang, F., Fowler, J. S., Zhu, W., Logan, J., Ma, Y., et al. (2009) · JAMA · doi:10.1001/jama.2009.1308 · Cited by 728 · cited 1×
“Full characteristics of the subjects have been described previously [5], so only a summary will be presented here.”
BackgroundSelf-citationdel Campo, N., Chamberlain, S. R., Sahakian, B. J., & Robbins, T. W. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.02.036 · Cited by 685
(2012) · PubMed · Cited by 526
Self-citationVolkow, N. D., Wang, G.-J., Newcorn, J., Telang, F., Solanto, M. V., Fowler, J. S., Logan, J., Ma, Y., Schulz, K., Pradhan, K., et al. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.8.932 · Cited by 331
Self-citationKuczenski, R., & Segal, D. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-16-07264.2002 · Cited by 316 · cited 1×
“Indeed, studies on the chronic effects of MPH have reported conflicting results with some documenting sensitization to the locomotor effects of MPH [21], others tolerance [22], and others no changes [23].”
BackgroundZahniser, N. R., & Doolen, S. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00158-9 · Cited by 310
Research works printed but not linked: 2
- Conners CK (1998) Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring. J Clin Psychiatry 59 Suppl 7: 24– 30. 9680050
- Volkow ND, Wang GJ, Tomasi D, Kollins S, Wigal T, et al (2013) Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with ADHD. Journal of neuroscience In press. PMC3350870 22262882
Cited by
Updated European Consensus Statement on diagnosis and treatment of adult ADHD
Kooij, J. J. S., Bijlenga, D., Salerno, L., Jaeschke, R., Bitter, I., Balázs, J., Thome, J., Dom, G., Kasper, S., Nunes Filipe, C., et al. (2019) · European Psychiatry · doi:10.1016/j.eurpsy.2018.11.001 · Cited by 686
Faraone, S. V. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.02.001 · Cited by 631
“In another study, in adults with ADHD, long-term MPH treatment increased striatal DAT availability (Wang et al., 2013).”
Evaluation of neurofeedback in ADHD: The long and winding road
Arns, M., Heinrich, H., & Strehl, U. (2014) · Biological Psychology · doi:10.1016/j.biopsycho.2013.11.013 · Cited by 404
Sustained effects of neurofeedback in ADHD: a systematic review and meta-analysis
Van Doren, J., Arns, M., Heinrich, H., Vollebregt, M. A., Strehl, U., & K. Loo, S. (2019) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-018-1121-4 · Cited by 361
Blum, K., Oscar-Berman, M., Demetrovics, Z., Barh, D., & Gold, M. S. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8726-5 · Cited by 187
Response Inhibition and Interference Control in Obsessive–Compulsive Spectrum Disorders
van Velzen, L. S., Vriend, C., de Wit, S. J., & van den Heuvel, O. A. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00419 · Cited by 169
Annual Research Review: Perspectives on progress in ADHD science – from characterization to cause
Sonuga‐Barke, E. J. S., Becker, S. P., Bölte, S., Castellanos, F. X., Franke, B., Newcorn, J. H., Nigg, J. T., Rohde, L. A., & Simonoff, E. (2023) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13696 · Cited by 157
Self-citationReal‐time f MRI neurofeedback in adolescents with attention deficit hyperactivity disorder
Alegria, A. A., Wulff, M., Brinson, H., Barker, G. J., Norman, L. J., Brandeis, D., Stahl, D., David, A. S., Taylor, E., Giampietro, V., et al. (2017) · Human Brain Mapping · doi:10.1002/hbm.23584 · Cited by 151
Christiansen, L., Beck, M. M., Bilenberg, N., Wienecke, J., Astrup, A., & Lundbye-Jensen, J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060841 · Cited by 138
Hinshaw, S. P., Arnold, L. E., & For the MTA Cooperative Group (2015) · WIREs Cognitive Science · doi:10.1002/wcs.1324 · Cited by 134
The dopamine transporter gene SLC6A3: multidisease risks
Reith, M. E. A., Kortagere, S., Wiers, C. E., Sun, H., Kurian, M. A., Galli, A., Volkow, N. D., & Lin, Z. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01341-5 · Cited by 124
Self-citationRubia, K., Criaud, M., Wulff, M., Alegria, A., Brinson, H., Barker, G., Stahl, D., & Giampietro, V. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2018.11.055 · Cited by 111
Pharmacotherapeutic strategies for treating cocaine use disorder—what do we have to offer?
Brandt, L., Chao, T. W.-C., Comer, S. D., & LEVIN, F. R. (2020) · Addiction · doi:10.1111/add.15242 · Cited by 94
Neurochemistry of Visual Attention
Lockhofen, D. E. L., & Mulert, C. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.643597 · Cited by 87
Milioni, A. L. V., Chaim, T. M., Cavallet, M., de Oliveira, N. M., Annes, M., dos Santos, B., Louzã, M., da Silva, M. A., Miguel, C. S., Serpa, M. H., et al. (2017) · Journal of Attention Disorders · doi:10.1177/1087054714554933 · Cited by 77
Curtin, K., Fleckenstein, A. E., Keeshin, B. R., Yurgelun-Todd, D. A., Renshaw, P. F., Smith, K. R., & Hanson, G. R. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0207-5 · Cited by 76
Salum, G. A., Sonuga-Barke, E., Sergeant, J., Vandekerckhove, J., Gadelha, A., Moriyama, T. S., Graeff-Martins, A. S., Manfro, G. G., Polanczyk, G., & Rohde, L. A. P. (2014) · Psychological Medicine · doi:10.1017/s0033291714000919 · Cited by 74
Lam, A. P., Matthies, S., Graf, E., Colla, M., Jacob, C., Sobanski, E., Alm, B., Rösler, M., Retz, W., Retz‐Junginger, P., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.4980 · Cited by 75
Impact of ADHD and cannabis use on executive functioning in young adults
Tamm, L., Epstein, J. N., Lisdahl, K. M., Molina, B., Tapert, S., Hinshaw, S. P., Arnold, L. E., Velanova, K., Abikoff, H., & Swanson, J. M. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.08.001 · Cited by 73
Self-citationBaroni, A., & Castellanos, F. X. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.08.005 · Cited by 67
Methylphenidate effects in the young brain: friend or foe?
Loureiro‐Vieira, S., Costa, V. M., Bastos, M. D. L., Carvalho, F. D., & Capela, J. P. (2017) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2017.04.002 · Cited by 67
Exercise Intervention in Treatment of Neuropsychological Diseases: A Review
Chen, Z., Lan, W., Yang, G., Li, Y., Xiang, J., Chen, L., Zhou, Y. N., & Li, S. (2020) · Frontiers in Psychology · doi:10.3389/fpsyg.2020.569206 · Cited by 59
Proebstl, L., Kamp, F., Manz, K. M., Krause, D., Adorjan, K., Pogarell, O. M., Koller, G., Soyka, M., Falkai, P., & Kambeitz, J. P. (2019) · European Psychiatry · doi:10.1016/j.eurpsy.2019.03.003 · Cited by 60
The Effects of Individual Upper Alpha Neurofeedback in ADHD: An Open-Label Pilot Study
Escolano, C., Navarro‐Gil, M., García‐Campayo, J., Congedo, M., & Mínguez, J. (2014) · Applied Psychophysiology and Biofeedback · doi:10.1007/s10484-014-9257-6 · Cited by 57
Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe
Huss, M., Chen, W., & Ludolph, A. G. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-015-0336-0 · Cited by 56
Reward Processing in Novelty Seekers: A Transdiagnostic Psychiatric Imaging Biomarker
Qi, S., Schumann, G., Bustillo, J., Turner, J. A., Jiang, R., Zhi, D., Fu, Z., Mayer, A. R., Vergara, V. M., Silva, R. F., et al. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.01.011 · Cited by 55
“More specifically, stimulants are the standard treatment for ADHD, and they work by increasing the availability of synaptic dopamine (51).”
BackgroundWiers, C. E., Lohoff, F. W., Lee, J., Muench, C., Freeman, C. R., Zehra, A., Marenco, S., Lipska, B. K., Auluck, P. K., Feng, N., et al. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14067 · Cited by 52
Self-citationSwanson, J. M. (2019) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2019.07.001 · Cited by 52
Self-citationDifferentiating neural reward responsiveness in autism versus ADHD
Kohls, G., Thönessen, H., Bartley, G. K., Grossheinrich, N., Fink, G. R., Herpertz-Dahlmann, B., & Konrad, K. (2014) · Developmental Cognitive Neuroscience · doi:10.1016/j.dcn.2014.08.003 · Cited by 50
Tao, R., Yang, Y., Wilson, M., Chang, J. R., Liu, C., & Sit, C. H. P. (2025) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/s12966-024-01702-7 · Cited by 48
Challenges of Treating ADHD with Comorbid Substance Use Disorder: Considerations for the Clinician
Barbuti, M., Maiello, M., Spera, V., Pallucchini, A., Brancati, G., Maremmani, A., Perugi, G., & Maremmani, I. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093096 · Cited by 47
“Similarly, a positron emission tomography (PET) study conducted on 18 ADHD adults before and after 12 months of methylphenidate (MPH) treatment revealed an up-regulation of DAT in the striatum of ADHD subjects compared to controls [36].”
BackgroundHandelman, K., & Sumiya, F. M. (2022) · Brain Sciences · doi:10.3390/brainsci12080959 · Cited by 46
Contribution of Clinical Neuroimaging to the Understanding of the Pharmacology of Methylphenidate
Zimmer, L. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.04.001 · Cited by 47
Coghill, D. (2019) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2019.07.002 · Cited by 45
Clock genes, ADHD and aggression
Mogavero, F., Jager, A., & Glennon, J. C. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.11.002 · Cited by 44
“, 2005), others no differences (Wang et al., 2013) or reduced DAT density compared to control subjects (Volkow et al.”
InfluentialRobison, L. S., Ananth, M. R., Hadjiargyrou, M., Komatsu, D. E., & Thanos, P. K. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1680-4 · Cited by 40
Network Structure among Brain Systems in Adult ADHD is Uniquely Modified by Stimulant Administration
Cary, R. P., Ray, S., Grayson, D. S., Painter, J. G., Carpenter, S. D., Maron, L. M., Sporns, O., Stevens, A. A., Nigg, J. T., & Fair, D. A. (2016) · Cerebral Cortex · doi:10.1093/cercor/bhw209 · Cited by 39
Cortese, S., Newcorn, J. H., & Coghill, D. (2021) · CNS Drugs · doi:10.1007/s40263-021-00848-3 · Cited by 38
Self-citationMohammadi, M. R., Malmir, N., Khaleghi, A., & Aminiorani, M. (2015) · PubMed Central · Cited by 37
Rosenau, P. T., Openneer, T. J. C., Matthijssen, A. M., van de Loo-Neus, G. H. H., Buitelaar, J. K., van den Hoofdakker, B. J., Hoekstra, P. J., & Dietrich, A. (2021) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13419 · Cited by 37
Sethi, A., Voon, V., Critchley, H. D., Cercignani, M., & Harrison, N. A. (2018) · Brain · doi:10.1093/brain/awy048 · Cited by 36
“Previous studies show long-term alterations in striatal dopamine availability following sustained methylphenidate use (Wang et al. , 2013).”
BackgroundIsfandnia, F., El Masri, S., Radua, J., & Rubia, K. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105703 · Cited by 36
Dopaminergic System Dysfunction in Recreational Dexamphetamine Users
Schrantee, A., Václavů, L., Heijtel, D., Caan, M. W. A., Gsell, W., Lucassen, P. J., Nederveen, A. J., Booij, J., & Reneman, L. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.301 · Cited by 35
Lensing, M. B., Zeiner, P., Sandvik, L., & Opjordsmoen, S. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m07714 · Cited by 34
Striatal Activation Predicts Differential Therapeutic Responses to Methylphenidate and Atomoxetine
Schulz, K. P., Bedard, A., Fan, J., Hildebrandt, T., Stein, M. A., Ivanov, I., Halperin, J. M., & Newcorn, J. H. (2017) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2017.04.005 · Cited by 33
Self-citationVéronneau-Veilleux, F., Robaey, P., Ursino, M., & Nekka, F. (2022) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2022.849323 · Cited by 32
de Azeredo, L. A., Rovaris, D. L., Mota, N. R., Polina, E. R., Marques, F. Z., Contini, V., Vitola, E. S., Belmonte-de-Abreu, P. S., Rohde, L. A., Grevet, E. H., et al. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0486-8 · Cited by 32
Changes in behavior as side effects in methylphenidate treatment: review of the literature
Konrad-Bindl, D. S., Gresser, U., & Richartz, B. M. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s114185 · Cited by 32
Young, S., Abbasian, C., Al‐Attar, Z., Branney, P., Colley, B., Cortese, S., Cubbin, S., Deeley, Q., Gudjonsson, G. H., Hill, P., et al. (2023) · World Journal of Psychiatry · doi:10.5498/wjp.v13.i3.84 · Cited by 30
Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?
Hammerness, P. G., Karampahtsis, C., Babalola, R., & Alexander, M. E. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1011620 · Cited by 30
Attention-deficit/hyperactivity disorder in adults: update on clinical presentation and care
Asherson, P. J., Manor, I., & Huß, M. (2014) · Neuropsychiatry · doi:10.2217/npy.14.16 · Cited by 30
Evidence-based prescribing of medications for ADHD: where are we in 2023?
Cortese, S. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2169604 · Cited by 28
Lam, S.-L., Criaud, M., Alegría, A. A., Barker, G. J., Giampietro, V., & Rubia, K. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102291 · Cited by 27
Criaud, M., Wulff, M., Alegría, A. A., Barker, G. J., Giampietro, V., & Rubia, K. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102311 · Cited by 27
Cervelló, X. C., Ramon, M., Cunill, R., Olivé, C., & Serrano, D. (2020) · Journal of Attention Disorders · doi:10.1177/1087054720903372 · Cited by 27
Differential long-term medication impact on executive function and delay aversion in ADHD
Morell, B. R., & Expósito, S. H. (2017) · Applied Neuropsychology Child · doi:10.1080/21622965.2017.1407653 · Cited by 28
Shalev, L., Kolodny, T., Shalev, N., & Mevorach, C. (2016) · Journal of Learning Disabilities · doi:10.1177/0022219415579125 · Cited by 28
Polina, E. R., Rovaris, D. L., de Azeredo, L. A., Mota, N. R., Vitola, E. S., Silva, K. L., Guimarães-da-Silva, P. O., Picon, F. A., Belmonte-de-Abreu, P. S., Rohde, L. A., et al. (2013) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8286-2 · Cited by 26
Differential Efficacy of Neurofeedback in Children with ADHD Presentations
Cueli, M., Rodríguez, C., Cabaleiro, P., García, T., & Castro, P. G. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8020204 · Cited by 25
Froehlich, T. E., Antonini, T. N., Brinkman, W. B., Langberg, J. M., Simon, J. O., Adams, R. E., Fredstrom, B. K., Narad, M. E., Kingery, K. M., Altaye, M., et al. (2014) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0000000000000025 · Cited by 23
Neurotherapeutics for ADHD : Do they work?
Rubia, K. (2022) · PsyCh Journal · doi:10.1002/pchj.544 · Cited by 23
The Effects of Stimulant Medication and Training on Sports Competence Among Children With ADHD
Altszuler, A. R., Morrow, A. S., Merrill, B. M., Hammer, S. N., Macphee, F. L., Gnagy, E. M., Greiner, A. R., Coxe, S. J., Raiker, J. S., Coles, E. K., et al. (2017) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374416.2016.1270829 · Cited by 23
Quansah, E., & Zetterström, T. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.01.016 · Cited by 20
Yan, C., Zhou, H., Wei, W., Wang, Y., Cui, L., Chan, R. C. K., & Deng, C. (2018) · Developmental Neuropsychology · doi:10.1080/87565641.2018.1487442 · Cited by 19
Lange, K. W. (2017) · University of Regensburg Publication Server (University of Regensburg) · doi:10.5283/mnhd.4 · Cited by 17
Evaluation of causality between ADHD and Parkinson's disease: Mendelian randomization study
Li, G. H., Ge, G. M., Cheung, C., Ip, P., Coghill, D., & Wong, I. C. K. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.06.001 · Cited by 17
Manza, P., Hu, S., Ide, J. S., Farr, O. M., Zhang, S., Leung, H., & Li, C. R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115625102 · Cited by 16
Schrantee, A., Bouziane, C., Bron, E. E., Klein, S., Bottelier, M. A., Kooij, J. J. S., Rombouts, S. A. R. B., & Reneman, L. (2017) · Brain Imaging and Behavior · doi:10.1007/s11682-017-9707-x · Cited by 16
Human Brain Imaging of Dopamine Transporters
Varrone, A., & Halldin, C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-418677-4.00009-9 · Cited by 16
Do food bioactives play a role in attention-deficit/hyperactivity disorder?
Lange, K. W. (2018) · Journal of Food Bioactives · doi:10.31665/jfb.2018.4160 · Cited by 16
Zhang, D., Johnstone, S. J., Sauce, B., Arns, M., Sun, L., & Jiang, H. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110802 · Cited by 15
Chu, C.-L., Lee, I. H., Chi, M. H., Chen, K. C., Chen, P. S., Yao, W. J., Chiu, N.-T., & Yang, Y. K. (2017) · CNS Spectrums · doi:10.1017/s1092852917000049 · Cited by 15
Xu, Y., & Li, Z. (2019) · Medicinal Research Reviews · doi:10.1002/med.21566 · Cited by 15
Shanok, N. A., Rodriguez, S., Muzac, S., Huertas Del Pino, C., Brown, L., & Rodriguez, R. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.05.066 · Cited by 14
Murkett, K., Sikirica, V., Hervas, A., Newcorn, J. H., Harpin, V., Robertson, B., & Huß, M. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s94158 · Cited by 14
Self-citationVaddadi, S., Czelatka, N., Gutierrez, B. D., Maddineni, B., Torres-Teran, C. D., Tron, D. N., McCall, K. L., & Piper, B. J. (2021) · PeerJ · doi:10.7717/peerj.12619 · Cited by 14
Rubia, K., Johansson, L. C., Carter, B., Stringer, D., Santosh, P., Mehta, M. A., Conti, A. A., Bozhilova, N. S., Eraydin, I. E., & Cortese, S. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05650-1 · Cited by 14
Lifestyle and attention deficit/hyperactivity disorder
Lange, K. W. (2018) · University of Regensburg Publication Server (University of Regensburg) · doi:10.5283/mnhd.10 · Cited by 14
The Benefits and Limitations of Stimulants in Treating ADHD
Coghill, D. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_331 · Cited by 13
Aster, H.-C., Romanos, M., Walitza, S., Gerlach, M., Mühlberger, A., Rizzo, A., Andreatta, M., Hasenauer, N., Hartrampf, P. E., Nerlich, K., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.804730 · Cited by 13
Effects of Methylphenidate on the Dopamine Transporter and Beyond
Zetterström, T., Quansah, E., & Grootveld, M. C. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_333 · Cited by 13
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults
Boesen, K., Danborg, P. B., Gøtzsche, P. C., & Jørgensen, K. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012857 · Cited by 12
Lanzo, A., Safratowich, B. D., Kudumala, S., Gallotta, I., Zampi, G., Schiavi, E. D., & Carvelli, L. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00576 · Cited by 12
Itagaki, S., Ohnishi, T., Toda, W., Sato, A., Matsumoto, J., Ito, H., Ishii, S., Yamakuni, R., Miura, I., & Yabe, H. (2024) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.177 · Cited by 12
Nooripour, R., Hosseinian, S., Afrouz, G. A., & Bakhshani, N. (2018) · international journal high risk behaviors & addiction · doi:10.5812/ijhrba.82012 · Cited by 12
Influence of DAT1 Promotor Methylation on Sports Performance
Grzywacz, A., Chmielowiec, K., Boroń, A., Michałowska‐Sawczyn, M., Chmielowiec, J., Trybek, G., Mroczek, B., Leźnicka, K., Cięszczyk, P., & Masiak, J. (2021) · Genes · doi:10.3390/genes12091425 · Cited by 11
Dutta, C. N., Christov‐Moore, L., Ombao, H., & Douglas, P. K. (2022) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.938501 · Cited by 10
Ulrich, M., Heckel, K., Kölle, M. A., & Grön, G. (2022) · Biology · doi:10.3390/biology11091320 · Cited by 10
Zhang, D., Johnstone, S. J., Li, H., Luo, X., & Sun, L. (2021) · Behaviour Change · doi:10.1017/bec.2021.26 · Cited by 9
Methylphenidate as a treatment option for substance use disorder: a transdiagnostic perspective
van Ruitenbeek, P., Franzen, L., Mason, N. L., Stiers, P. L. J., & Ramaekers, J. G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1208120 · Cited by 9
Zhang, X., Talpos, J. C., Berridge, M. S., Apana, S. M., Slikker, W., Wang, C., & Paule, M. G. (2021) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2021.107017 · Cited by 8
Miceli, M. D., Derf, A., & Gronier, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158588 · Cited by 9
Ogrodnik, M., Karsan, S., Cirone, V., & Heisz, J. J. (2023) · Brain Sciences · doi:10.3390/brainsci13040673 · Cited by 7
Electroencephalogram Neurofeedback: Application in ADHD and Epilepsy
Mayer, K., & Arns, M. (2016) · Psychiatric Annals · doi:10.3928/00485713-20160906-01 · Cited by 7
Lange, K. W., Reißmann, A., Nakamura, Y., & Lange, K. M. (2023) · Food Science and Human Wellness · doi:10.26599/fshw.2022.9250146 · Cited by 7
Duval, F., Erb, A., Mokrani, M., Weiss, T., & Carcangiu, R. (2021) · Psychiatric Research and Clinical Practice · doi:10.1176/appi.prcp.20210010 · Cited by 7
Rosenau, P. T., van den Hoofdakker, B. J., Matthijssen, A. M., van de Loo-Neus, G. H. H., Buitelaar, J. K., Hoekstra, P. J., & Dietrich, A. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.06.014 · Cited by 7
Khodaverdi, Z., Moreau, D., & Garber, C. E. (2021) · Child Neuropsychology · doi:10.1080/09297049.2021.1992378 · Cited by 6
Schaer, R., Wenger, N., Steiner, S., Notter, T., & Meyer, U. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02373-7 · Cited by 6
Stimulant Withdrawal in a Child with Autism Spectrum Disorder and ADHD - A Case Report.
Krakowski, A. D., & Ickowicz, A. (2018) · Europe PMC (PubMed Central) · Cited by 6
Metadata
- Authors
- Wang, G.-J., Volkow, N. D., Wigal, T., Kollins, S. H., Newcorn, J. H., Telang, F., Logan, J., Jayne, M., Wong, C. T., Han, H., Fowler, J. S., Zhu, W., & Swanson, J. M.
- Affiliations
- Brookhaven National Laboratory (US)
- National Institutes of Health (US)
- University of California, Irvine (US)
- Duke University (US)
- Icahn School of Medicine at Mount Sinai (US)
- Stony Brook University (US)
- Corresponding author
- Wang, Gene-Jack
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-15
- Volume
- 8
- Issue
- 5
- Pages
- e63023
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3655054
- OpenAlex
- W2059137431
- Cited by
- 144
- References
- 29
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 9 · 2023: 11 · 2022: 13 · 2021: 15 · 2020: 8 · 2019: 8 · 2018: 14 · 2017: 15 · 2016: 10 · 2015: 8 · 2014: 15 · 2013: 5
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Energy (DE‐ACO2‐76CH00016, 76CH00016)
- Orexigen Therapeutics
- Stony Brook University
- National Institutes of Health
- National Institute on Alcohol Abuse and Alcoholism (Z01AA000550)
- National Institute of Mental Health (R01MH066961)
- National Center for Research Resources (M01RR010710)
- Biological and Environmental Research
- Brookhaven National Laboratory (DE-ACO2-76CH00016)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- attention deficit hyperactivity disorder, dopamine transporter, methylphenidate, striatum, caudate nucleus, putamen, ventral striatum, treatment efficacy, adult ADHD
- MeSH terms
- Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Caudate Nucleus, Cocaine, Female, Humans, Male, Methylphenidate, Putamen, Case-Control Studies, Radiopharmaceuticals, Positron-Emission Tomography, Dopamine Plasma Membrane Transport Proteins, Young Adult, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.